Natural Selection, Inc. Personnel Commended With 2010 FDA Honor Award for Effort on PREDICT

Jun 09, 2010, 18:59 ET from Natural Selection, Inc.

SAN DIEGO, June 9 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) recently announced that members of the PREDICT Enterprise Project Development Team including personnel from Natural Selection, Inc. (NSI) have received a 2010 FDA Honor Award. The award "for design, development, testing, evaluation, and support of PREDICT, FDA's new system to improve public health through better targeting of imported products for examination" was given to the entire team working on the PREDICT tool for the FDA.

According to the FDA, the number of international shipments of consumer products entering the United States each year is in excess of 20 million and growing each year. The Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting (PREDICT) screening system reduces the risk of potentially unsafe products entering the commercial sector, and expedites the entry rate for those products that are in compliance with FDA regulations. Increasing the efficiency and efficacy of FDA inspectors is a top priority of the current Administration.

NSI's involvement on the Enterprise Project Development Team is led by company President V. William Porto, with Senior Staff Scientist Sevan Ficici, and Staff Scientists Michael Berg and Enoch Liu also involved on the project. "Working with the FDA on the PREDICT project has provided a tremendous opportunity to showcase NSI's engineering talent.  We are grateful that the FDA has recognized the dedication and hard work that our staff have put into making this project a success," said Bill Porto. The award was accepted on June 3, 2010 by Sylvia Thomas at the 50th Annual FDA Honor Awards Ceremony in Silver Spring, Maryland on behalf of the entire PREDICT team.

Natural Selection, Inc. was founded in 1993 to address complex problems in industry, medicine, and defense. The company possesses unique expertise in computational intelligence techniques, including evolutionary computation, neural networks, and fuzzy logic. The corporation's research efforts support the discovery of new pharmaceuticals, the automated detection and discovery of important patterns and processes, computer-assisted diagnosis, and a variety of military and industrial projects.

For more information, please contact:

Mr. V. William Porto


Natural Selection, Inc.

9330 Scranton Rd.

Suite 150

San Diego, CA, 92121

tel: (858) 455-6449

fax: (858) 455-1560

bporto [at]

and please visit our web site at

SOURCE Natural Selection, Inc.